Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 238-289-2 | CAS number: 14338-82-0
Dermal absorption
Administrative data
- Endpoint:
- dermal absorption
- Type of information:
- (Q)SAR
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: QSAR estimations for dermal absorption tend to be conservative; however, they are not formally validated
- Justification for type of information:
- QSAR prediction: migrated from IUCLID 5.6
Data source
Reference
- Reference Type:
- other: database
- Title:
- EpiSuite DermWin V2.02
- Author:
- US EPA
Materials and methods
- Principles of method if other than guideline:
- The US-EPA EpiSuite reports DERMWINv.2.02 calculations. These are based on the Guy & Potts formula (GUY R.H. AND POTTS R.O., 1992. Structure-Permeability Relationships in Percutaneous absorption. J. Pharm. Sci.. 81: 603-604).
- GLP compliance:
- no
Test material
- Reference substance name:
- Dibutyl methylenedithiodi(acetate)
- EC Number:
- 238-289-2
- EC Name:
- Dibutyl methylenedithiodi(acetate)
- Cas Number:
- 14338-82-0
- Molecular formula:
- C13H24O4S2
- IUPAC Name:
- butyl 2-({[(2-butoxy-2-oxoethyl)sulfanyl]methyl}sulfanyl)acetate
- Reference substance name:
- MBTester
- IUPAC Name:
- MBTester
Constituent 1
Constituent 2
Results and discussion
Percutaneous absorption
- Parameter:
- percentage
- Absorption:
- <= 10 %
- Remarks on result:
- other: 8 h
- Remarks:
- Concluded on the basis of the very low predicted absorption rate of 0.00003 mg/cm²/event.
Applicant's summary and conclusion
- Conclusions:
- It is concluded that absorption of MBTester through human skin in vivo within 8 h will be significantly less than 10%. This is a very conservative assumption and can be used for dermal risk assessments and setting of dermal DNELs.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
